FrancophonIA/ELRC3.0 huggingface dataset:
English: P-gp and moderate CYP3A inhibitor
Estonian: P-gp ja mõõdukas CYP3A inhibiitor
English: Avatrombopag is an orally active, small molecule thrombopoietin (TPO) receptor agonist that stimulates proliferation and differentiation of megakaryocytes from bone marrow progenitor cells resulting in increased production of platelets.
Estonian: Avatrombopaag on suu kaudu manustamisel toimiv väikesemolekuline trombopoetiini (TPO) retseptori agonist, mis stimuleerib megakarüotsüütide proliferatsiooni ja diferentseerumist luuüdi eellasrakkudest, mille tulemusena suureneb trombotsüütide produktsioon.
English: However, administration of avatrombopag with both a high- and low-fat meal reduced inter-subject and intra-subject pharmacokinetic variability of avatrombopag by approximately 50%.
Estonian: Kuid avatrombopaagi manustamine suure ja vähese rasvasisaldusega toidukorraga vähendas avatrombopaagi farmakokineetika isikutevahelist ja samal isikul varieerumist ligikaudu 50%.
English: • blood clot in the portal vein (blood vessel that carries blood to the liver from the intestines)
Estonian: • verehüüve portaalveenis (soolest maksa verd kandev veresoon), mis võib põhjustada valu või turset ülakõhus;
English: The apparent volume of distribution of avatrombopag in patients with thrombocytopenia and chronic liver disease based on population pharmacokinetic analysis is approximately 180 L, suggesting that avatrombopag is extensively distributed.
Estonian: Avatrombopaagi jaotumismaht trombotsütopeenia ja kroonilise maksahaigusega patsientidel on populatsiooni farmakokineetika analüüsi põhjal ligikaudu 180 l, mis näitab avatrombopaagi ulatuslikku jaotumist.
English: Each film-coated tablet contains 120.8 mg of lactose monohydrate.
Estonian: Teadaolevat toimet omav abiaine Üks õhukese polümeerikattega tablett sisaldab 120,8 mg laktoosmonohüdraati.
English: Doptelet is used in adults with chronic liver disease to treat low platelet count (called thrombocytopenia) before having a medical procedure where there is a risk of bleeding.
Estonian: Dopteleti kasutatakse kroonilise maksahaigusega patsientidel trombotsüütide vähesuse (ehk trombotsütopeenia) raviks enne meditsiinilisi protseduure, millega kaasneb verejooksude oht.
English: Tablet core: lactose monohydrate (see section 2 “Doptelet contains lactose”); microcrystalline cellulose [E460(i)]; crospovidone type B [E1202]; silica, colloidal anhydrous [E551]; magnesium stearate [E470b].
Estonian: Tableti tuum: laktoosmonohüdraat (vt lõik 2 „Doptelet sisaldab laktoosi“); mikrokristalliline tselluloos [E460)(i)]; krospovidoon, B-tüüpi [E1202]; kolloidne ränidioksiid, veevaba [E551]; magneesiumstearaat [E470b].
English: Concomitant use of avatrombopag with strong CYP3A4/5 or CYP2C9 inhibitors increases avatrombopag exposure.
Estonian: Avatrombopaagi kasutamisel tugevate CYP3A4/5 või CYP2C9 inhibiitoritega suureneb avatrombopaagi kontsentratsioon.
English: Hypergastrinemia-related gastric carcinoids in rodents are generally considered to be of low risk or relevance to humans.
Estonian: Hüpergastrineemiaga seotud mao kartsinoide närilistel risk inimestele on väike või vähe oluline.
English: Co-administration of avatrombopag with either a high-fat or low-fat meal did not result in clinically important changes in rate or extent of absorption of avatrombopag.
Estonian: Avatrombopaagi manustamine koos suure või vähese rasvasisaldusega toidukorraga ei mõjutanud kliiniliselt oluliselt avatrombopaagi imendumise kiirust ega ulatust.
English: Avatrombopag was not mutagenic in an in vitro bacterial reverse mutation (AMES) assay or clastogenic in an in vitro human lymphocyte chromosomal aberrations assay or in an in vivo rat bone marrow micronucleus assay.
Estonian: Avatrombopaag ei olnud mutageenne in vitro bakterite pöördmutatsiooni (AMES) testis ega klastogeenne in vitro inimese lümfotsüütide kromosoomi kõrvalekallete analüüsis ega in vivo rottide luuüdi mikrotuumade analüüsis.
English: Film coating: poly(vinyl alcohol) [E1203]; talc [E553b]; macrogol 3350 [E1521]; titanium dioxide [E171]; iron oxide yellow [E172].
Estonian: Õhuke polümeerikate: polüvinüülalkohol [E1203]; talk (E553b); makrogool 3350 [E1521]; titaandioksiid [E171]; kollane raudoksiid [E172].
English: Doptelet works by helping to increase the number of platelets in the blood.
Estonian: Dopteleti toimel suureneb trombotsüütide arv veres.
English: There is limited information on the use of avatrombopag in patients previously exposed to avatrombopag.
Estonian: Avatrombopaagi kasutamise kohta patsientidel, kellel on varem avatrombopaagi kasutatud, on vähe andmeid.
English: High baseline platelet count (≥ 40 to < 50 x 109/L)
Estonian: Suur ravieelne trombotsüütide arv (≥ 40 kuni < 50 x 109/l).
English: If you have any questions on the use of this medicine, ask your doctor or pharmacist.
Estonian: Kui teil on lisaküsimusi selle ravimi kasutamise kohta, pidage nõu oma arsti või apteekriga.
English: Concomitant use of avatrombopag with P-gp inhibitors resulted in alterations in exposure that were not clinically significant.
Estonian: Avatrombopaagi samaaegsel kasutamisel P-gp inhibiitoritega ei olnud muutused kontsentratsioonides kliiniliselt olulised.
English: Table 2: Efficacy results by baseline platelet count cohort and treatment group - Study 1 and Study 2
Estonian: Efektiivsusega seotud tulemused ravieelse trombotsüütide arvu kohortide ja ravirühmade järgi - 1. ja 2. uuringus
English: Doptelet was not studied in patients with prior thromboembolic events.
Estonian: Dopteleti kasutamist patsientidel, kellel on esinenud trombemboolia nähte, ei uuritud.
English: Each carton contains one blister of 10 or 15 film-coated tablets.
Estonian: Karbis sisaldub üks blister 10 või 15 õhukese polümeerikattega tabletiga.
English: CYP3A4/5 and CYP2C9 inhibitors
Estonian: CYP3A4/5 ja CYP2C9 inhibiitorid
English: No clinically important difference in avatrombopag exposures were observed between patients with Child-Turcotte-Pugh Scores (Range = 5 to 12) or MELD scores (Range = 4 to 23) and healthy subjects.
Estonian: Avatrombopaagi kontsentratsioonide kliiniliselt olulisi erinevusi patsientidel, kellel olid Child-Turcotte-Pugh-skoorid vahemikus = 5 kuni 12 või MELD-skoorid vahemikus = 4 kuni 23, võrreldes tervete vabatahtlikega ei täheldatud.
English: Lactose monohydrate Microcrystalline cellulose (E460(i)) Crospovidone type B (E1202) Silica, colloidal anhydrous (E551) Magnesium stearate (E470b)
Estonian: Laktoosmonohüdraat Mikrokristalliline tselluloos (E460(i)) Krospovidoon, B-tüüpi (E1202) Kolloidne ränidioksiid, veevaba (E551) Magneesiumstearaat (E470b)
English: The population pharmacokinetic analysis of avatrombopag in healthy subjects and subjects with thrombocytopenia due to chronic liver disease indicated similar exposures between healthy subjects and subjects with mild and moderate renal impairment (CrCL ≥ 30 mL/min, Cockcroft-Gault).
Estonian: Avatrombopaagi populatsiooni farmakokineetika analüüs tervetel uuringus osalejatel ja kroonilisest maksahaigusest põhjustatud trombotsütopeeniaga patsientidel näitas, et tervetel vabatahtlikel ja kerge ja mõõduka neerukahjustusega uuringus osalejatel (kreatiniini kliirens ≥ 30 ml/min, Cockcroft-Gault) on kontsentratsioonid sarnased.
English: Strong CYP3A4/5 or CYP2C9 inducers
Estonian: Tugevad CYP3A4/5 või CYP2C9 indutseerijad
English: Moderate CYP2C9 and strong CYP3A inducer
Estonian: Mõõdukas CYP2C9 ja tugev CYP3A indutseerija
English: No dosage adjustment is necessary for patients with mild (Child-Pugh class A) to moderate (Child-Pugh class B) hepatic impairment.
Estonian: Kerge (Child-Pugh A-klass) kuni mõõduka (Child-Pugh B-klass) maksakahjustusega patsientidel ei ole annuse kohandamine vajalik.
English: Doptelet 20 mg tablets avatrombopag
Estonian: Doptelet 20 mg tabletid Avatrombopaag
English: Population pharmacokinetic analysis of avatrombopag plasma concentrations from the clinical studies with healthy subjects and patients with thrombocytopenia due to chronic liver disease indicated that avatrombopag exposures were similar across the different races studied.
Estonian: Avatrombopaagi plasmakontsentratsioonide populatsiooni farmakokineetika analüüs kliinilistes uuringutes tervete uuringus osalejatega ja kroonilisest maksahaigusest põhjustatud trombotsütopeeniaga patsientidega näitasid, et avatrombopaagi kontsentratsioonid olid kõigil uuritud rassidel sarnased.
English: Moderate CYP3A and CYP2C9 inhibitor
Estonian: Mõõdukas CYP3A ja CYP2C9 inhibiitor
English: There is limited information on the use of avatrombopag in patients with severe (Child-Pugh class C, MELD score > 24) hepatic impairment.
Estonian: Avatrombopaagi kasutamise kohta raske (Child-Pugh C-klass, MELD skoor > 24) maksakahjustusega patsientidel on andmed piiratud.
English: Mean platelet count (+/- standard error) by days from start of dosing by baseline platelet count cohort and treatment group - pooled Study 1 and Study 2
Estonian: Keskmine trombotsüütide arv (±standardviga) eri päevadel alates annustamise algusest, ravieelsete trombotsüütide arvu kohortide ja ravirühmade järgi - 1. ja 2. uuringu koondandmed
English: If any of the above applies to you, or you are not sure, talk to your doctor or pharmacist before taking Doptelet.
Estonian: Kui mõni eeltoodud hoiatustest puudutab teid või teil on selle suhtes kahtlusi, pidage enne Dopteleti kasutamist nõu arsti või apteekriga.
English: Portal vein thrombosis has been reported at an increased frequency in patients with chronic liver disease who had platelet counts > 200 x 109/L receiving a thrombopoietin receptor agonist (see section 4.8).
Estonian: Kroonilise maksahaigusega patsientidel, kellel olid trombotsüütide arvud > 200 x 109/l ja kes said ravi trombopoetiini retseptori agonistiga, suurenes portaalveeni tromboosi esinemissagedus (vt lõik 4.8).
English: Low baseline platelet count cohort (< 40 x 109/L)
Estonian: Väike ravieelne trombotsüütide arv (< 40 x 109/l).
English: In each study, patients were assigned to the low baseline platelet count cohort (˂ 40 x 109/L) or the high baseline platelet count cohort (≥ 40 to ˂ 50 x 109/L) based on their platelet count at baseline.
Estonian: (˂ 40 x 109/l) või suure ravieelse trombotsüütide arvuga kohorti (≥ 40 kuni ˂ 50 x 109/l), lähtudes nende ravieelsest trombotsüütide arvust.
English: Placebo (n = 34)
Estonian: Platseebo (n = 34)
English: Placebo (n = 48)
Estonian: Platseebo (n = 48)
English: Strong CYP3A inhibitor
Estonian: Tugev CYP3A4 inhibiitor
English: Avatrombopag was present in milk of lactating rats after oral administration of radioactive labeled avatrombopag.
Estonian: Avatrombopaag sisaldus pärast radiomärgistusega avatrombopaagi suukaudset manustamist lakteerivate rottide piimas.
English: D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
Estonian: D. RAVIMI OHUTU JA EFEKTIIVSE KASUTAMISE TINGIMUSED JA PIIRANGUD • Riskijuhtimiskava
English: Placebo (n = 33)
Estonian: Platseebo (n = 33)
English: The predominant route of avatrombopag excretion is via faeces.
Estonian: Avatrombopaag eritub valdavalt väljaheitega.
English: What you need to know before you take Doptelet 3.
Estonian: 1. Mis ravim on Doptelet ja milleks seda kasutatakse 2. Mida on vaja teada enne Dopteleti võtmist 3.
English: Placebo (n = 43)
Estonian: Platseebo (n = 43)
English: Two doses should not be taken at one time to make up for a missed dose.
Estonian: Ei tohi võtta kahekordset annust, kui annus jäi eelmisel korral võtmata.
English: In the low baseline platelet count cohort, the mean baseline platelet count for the avatrombopag-treated group was 31.1 x 109/L and for placebo-treated patients was 30.7 x 109/L.
Estonian: Väikese ravieelse trombotsüütide arvuga kohordis oli avatrombopaagiga ravitud rühmas keskmine ravieelne trombotsüütide arv 31,1 x 109/l ja platseeborühmas 30,7 x 109/l.
English: If you are breast-feeding, ask your doctor or pharmacist for advice before taking Doptelet.
Estonian: Kui imetate last, pidage enne Dopteleti kasutamist nõu oma arsti või apteekriga.
English: In the low baseline platelet count cohort, the mean baseline platelet count for the avatrombopag-treated group was 32.7 x 109/L and for placebo-treated patients was 32.5 x 109/L.
Estonian: Väikese ravieelse trombotsüütide arvuga kohordis oli avatrombopaagiga ravitud rühmas keskmine ravieelne trombotsüütide arv 32,7 x 109/l ja platseeborühmas 32,5 x 109/l.
English: Musculoskeletal & connective tissue disorders
Estonian: Lihaste, luustiku ja sidekoe kahjustused luuvalu müalgia
English: Package leaflet: Information for the patient Doptelet 20 mg film-coated tablets avatrombopag This medicine is subject to additional monitoring.
Estonian: Pakendi infoleht: teave patsiendile Doptelet 20 mg õhukese polümeerikattega tabletid
English: In the high baseline platelet count cohort, the mean baseline platelet count for the avatrombopag-treated patients was 44.3 x 109/L and for placebo-treated patients was 44.9 x 109/L.
Estonian: Suure ravieelse trombotsüütide arvuga kohordis oli avatrombopaagiga ravitud patsientidel keskmine ravieelne trombotsüütide arv 44,3 x 109/l ja platseeborühmas 44,9 x 109/l.
English: If a dose is missed, it should be taken as soon as it is remembered.
Estonian: Vahelejäänud annus tuleb manustada niipea kui võimalik.
English: Doptelet 20 mg film-coated tablets
Estonian: Doptelet 20 mg õhukese polümeerikattega tabletid
English: If you are not sure, talk to your doctor or pharmacist before taking Doptelet.
Estonian: Kahtluste korral pidage enne Dopteleti kasutamist nõu oma arsti või apteekriga.
English: In the high baseline platelet count cohort, the mean baseline platelet count for the avatrombopag-treated patients was 44.3 x 109/L and for placebo-treated patients was 44.5 x 109/L.
Estonian: Suure ravieelse trombotsüütide arvuga kohordis oli avatrombopaagiga ravitud rühmas keskmine ravieelne trombotsüütide arv 44,3 x 109/l ja platseeborühmas 44,5 x 109/l.
English: Avatrombopag 60 mg (n = 70) Proportion of subjects not requiring a platelet transfusion or rescue procedure for bleeding Responders 95% CIa P-valueb Proportion of subjects who achieved a platelet count ≥ 50 × 109/L on procedure day Responders 95% CIa P-valueb Change in platelet count from baseline to procedure day Mean (SD) x 109/L Median x 109/L P-valuec
Estonian: Avatrombopaa g 60 mg (n = 70) Uuringus osalejate osakaal, kes ei vajanud trombotsüütide ülekannet ega päästvat protseduuri verejooksu tõttu Ravivastusega osalejad 95% usaldusvahemika P-väärtusb
English: Renal impairment
Estonian: Vahelejäänud annused
English: Memantine Accord should be given once a day at the same time every day.
Estonian: Memantine Accordi peab võtma üks kord ööpäevas, iga päev samal kellaajal.
English: The full EPAR for Memantine Accord can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Memantine Accordi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The company provided data on the medicine's solubility, composition and absorption in the body.
Estonian: Ettevõte esitas andmed ravimi lahustuvuse, koostise ja imendumise kohta.
English: A risk management plan has been developed to ensure that Memantine Accord is used as safely as possible.
Estonian: Töötati välja riskijuhtimisstrateegia, et tagada Memantine Accordi võimalikult ohutu kasutamine.
English: ‘Bioequivalent' means that the medicines are expected to produce the same levels of the active substance in the body.
Estonian: Bioekvivalentne tähendab, et ravimid tekitavad organismis eeldatavalt sama toimeainesisalduse.
English: The tolerance and dose should be assessed within three months after starting treatment, and from then on the benefits of continuing treatment with Memantine Accord should be re-assessed on a regular basis.
Estonian: Ravimi taluvust ja annust tuleb hinnata 3 kuu jooksul alates ravi algusest, seejärel tuleb Memantine Accordiga ravi jätkamise kasulikkust regulaarselt uuesti hinnata.
English: Treatment should only be started if a caregiver is available who will regularly monitor the use of Memantine Accord by the patient.
Estonian: Ravi tohib alustada vaid juhul, kui on olemas hooldaja, kes jälgib regulaarselt, kuidas patsient Memantine Accordi kasutab.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Memantine Accord on 04 December 2013.
Estonian: Euroopa Komisjon andis Memantine Accordi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 04. detsembril 2013.
English: What measures are being taken to ensure the safe and effective use of Memantine Accord?
Estonian: Mis meetmed võetakse, et tagada Memantine Accordi ohutu ja efektiivne kasutamine?
English: The Committee recommended that Memantine Accord be approved for use in the EU.
Estonian: Komitee soovitas Memantine Accordi kasutamise Euroopa Liidus heaks kiita.
English: Memantine Accord is available as tablets (5 mg, 10 mg, 15 mg and 20 mg) and can only be obtained with a prescription.
Estonian: Memantine Accord on retseptiravim, mida turustatakse tablettidena (5 mg, 10 mg, 15 mg ja 20 mg).
English: It is used to treat patients with moderate to severe Alzheimer's disease, a type of dementia (a brain disorder) that gradually affects memory, intellectual ability and behaviour.
Estonian: See on dementsuse (teatud ajuhäire) liik, mis kahjustab järk-järgult mälu, vaimseid võimeid ja käitumist.
English: To prevent side effects, the dose of Memantine Accord is gradually increased over the first three weeks of treatment: during the first week, the daily dose is 5 mg; in the second week, it is 10 mg; and during the third week, it is 15 mg. From week four onwards, the recommended maintenance dose is 20 mg once a day.
Estonian: Kõrvalnähtude ennetamiseks suurendatakse Memantine Accordi annust esimese kolme ravinädala jooksul järk-järgult: esimesel nädalal on annus 5 mg, teisel 10 mg ning kolmandal 15 mg.
English: Memantine works by blocking types of receptors called N-methyl-D-aspartate (NMDA) receptors, to which the neurotransmitter glutamate normally attaches.
Estonian: Memantiini toime seisneb selles, et see blokeerib teatud retseptoreid (NMDA-retseptoreid), millele tavaliselt kinnitub neurotransmitter glutamaat.
English: Because Memantine Accord is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Memantine Accord on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: Memantine Accord memantine
Estonian: Memantine Accord memantiin
English: Therefore, the CHMP's view was that, as for Axura, the benefit outweighs the identified risk.
Estonian: Seetõttu on inimravimite komitee arvamusel, et nagu ka Axura korral, ületab ravimi kasulikkus sellega kaasnevad riskid.
English: This means that Memantine Accord is similar to a ‘reference medicine' already authorised in the European Union (EU) called Axura.
Estonian: See tähendab, et Memantine Accord on sarnane võrdlusravimiga Axura, millel juba on Euroopa Liidus müügiluba.
English: What is Memantine Accord and what is it used for?
Estonian: Mis on Memantine Accord ja milleks seda kasutatakse?
English: This is a summary of the European public assessment report (EPAR) for Memantine Accord.
Estonian: See on ravimi Memantine Accord Euroopa avaliku hindamisaruande kokkuvõte.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Memantine Accord, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Strateegiast lähtudes lisati Memantine Accordi omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: For practical information about using Memantine Accord, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Memantine Accordi kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: No additional studies in patients were required as Memantine Accord was shown to have comparable quality and is considered to be bioequivalent to the reference medicine, Axura.
Estonian: Lisauuringuid patsientidega ei olnud vaja, sest tõendatud on Memantine Accordi võrdväärne kvaliteet ja bioekvivalentsus võrdlusravimiga Axura.
English: It is not intended to provide practical advice on how to use Memantine Accord.
Estonian: Hindamisaruandes ei anta Memantine Accordi kasutamise praktilisi nõuandeid.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Memantine Accord has been shown to have comparable quality and is considered bioequivalent to Axura.
Estonian: Inimravimite komitee järeldas, et Euroopa Liidu nõuete kohaselt on tõendatud ravimi Memantine Accordi võrdväärne kvaliteet ja bioekvivalentsus ravimiga Axura.
English: For more information about treatment with Memantine Accord, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Memantine Accordiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Memantine Accord is a ‘generic medicine'.
Estonian: Memantine Accord on geneeriline ravim.
English: Memantine Accord is a medicine that contains the active substance memantine.
Estonian: Memantine Accord on ravim, mis sisaldab toimeainena memantiini.
English: Other information about Memantine Accord
Estonian: Muu teave Memantine Accordi kohta
English: Why is Memantine Accord approved?
Estonian: Miks Memantine Accord heaks kiideti?
English: The active substance in Memantine Accord, memantine, is an antidementia medicine.
Estonian: Memantine Accordi toimeaine memantiin on dementsuse ravim.
English: How is Memantine Accord used?
Estonian: Kuidas Memantine Accordi kasutatakse?
English: How has Memantine Accord been studied?
Estonian: Kuidas Memantine Accordi uuriti?
English: How does Memantine Accord work?
Estonian: Kuidas Memantine Accord toimib?
English: What are the benefits and risks of Memantine Accord?
Estonian: Milles seisneb Memantine Accordi kasulikkus ja mis riskid ravimiga kaasnevad?
English: Although this difference is not large, it may benefit some patients.
Estonian: Ehkki erinevus ei ole suur, võib sellest mõnele patsiendile kasu olla.
English: Further information on Alpivab can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Lisateave Alpivabi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What measures are being taken to ensure the safe and effective use of Alpivab?
Estonian: Mis meetmed võetakse, et tagada Alpivabi ohutu ja efektiivne kasutamine?
English: Alpivab (peramivir)
Estonian: Alpivab (peramiviir)
English: The European Medicines Agency decided that Alpivab's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Alpivabi kasulikkus on suurem kui sellega kaasnevad riskid, ja lubati ravimi kasutamine ELis.
English: What is Alpivab and what is it used for?
Estonian: Mis on Alpivab ja milleks seda kasutatakse?
English: There is a risk of severe allergic reactions, and although it is not known exactly how often these reactions occur, they appear to be rare.
Estonian: Alpivabiga seostatakse raskete allergiliste reaktsioonide riski ning kuigi nende reaktsioonide täpne esinemissagedus ei ole teada, on need tõenäoliselt harvad.
English: Alpivab (peramivir) EMA/120516/2018
Estonian: Alpivab (peramiviir) EMA/120516/2018
English: Alpivab is given as an infusion lasting 15 to 30 minutes.
Estonian: Alpivabi manustatakse 15-30 minutit kestva infusioonina.
English: Other information about Alpivab
Estonian: Muu teave Alpivabi kohta